Seaweed Extract May Hold Key to Halting Parkinson's Disease

New Research Discovery

Researchers at Johns Hopkins Medicine have identified a potential new biological target for halting Parkinson's disease. The target is α-synuclein, a protein that forms toxic oligomers and fibrils that are behind neurodegeneration in the disease.

Ecklonia Cava, a Seaweed Extract

The researchers found that an extract from the seaweed Ecklonia cava can inhibit the growth of α-synuclein oligomers and fibrils, thereby potentially offering a new therapeutic approach for Parkinson's disease.

Antioxidant Properties

Ecklonia cava extract is rich in antioxidants, which can help to combat oxidative stress, a major contributor to Parkinson's disease. The extract has also been shown to promote glucose absorption and alleviate oxidative stress.

Further Research Needed

While these findings are promising, further research is needed to validate the effectiveness and safety of Ecklonia cava extract in treating Parkinson's disease. Clinical trials are necessary to determine the optimal dosage and frequency of administration.